BusinessAchillion to Present at the Leerink Partners 7th Annual Global Healthcare ConferenceBy Nasdaq OMXFeb 9, 2018, 11:05 AM UTC
BusinessAchillion Initiates Phase I First-In Study of ACH-5228, a Next-Generation Oral Small Molecule Inhibitor of Complement Factor DBy Nasdaq OMXDec 20, 2017, 11:05 AM UTC
BusinessAchillion Reports Third Quarter 2017 Financial Results and Provides Update on Clinical ProgramsBy Nasdaq OMXNov 1, 2017, 8:06 PM UTC
BusinessUSPTO Grants Composition of Matter Patent to Achillion for ACH-4471, First-in-Class Small Molecule Complement Alternative Pathway Factor D InhibitorBy Nasdaq OMXOct 24, 2017, 10:05 AM UTC
BusinessAchillion Reports Second Quarter 2017 Financial Results and Proof-of-Concept With a First-in-Class, Oral Factor D InhibitorBy Nasdaq OMXAug 8, 2017, 8:02 PM UTC
BusinessAchillion Reports First Quarter 2017 Financial Results and Provides Update on Clinical ProgramsBy Nasdaq OMXMay 4, 2017, 10:05 AM UTC
BusinessAchillion Announces Initiation of Patient Dosing in Phase 2 Study of ACH-4471 for Paroxysmal Nocturnal HemoglobinuriaBy Nasdaq OMXApr 6, 2017, 10:05 AM UTC
